ProCE Banner Activity

Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer

Podcast Episodes
Listen to Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, as they discuss the clinical data that inform how they select later-line treatment for patients with mCRC.

Released: December 17, 2021

Expiration: December 16, 2022

Share

Faculty

Chiara Cremolini

Chiara Cremolini, MD, PhD

Medical Oncologist
Unit of Medical Oncology 2
Azienda Ospedaliero-Universitaria Pisana
Professor
Department of Translational Research and New Technologies in Medicine and Surgery
University of Pisa
Pisa, Italy

Teresa Macarulla

Teresa Macarulla, MD

Medical Oncologist
Vall d Hebron Institute of Oncology
Barcelona, Spain

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Faculty Disclosure

Primary Author

Chiara Cremolini, MD, PhD

Medical Oncologist
Unit of Medical Oncology 2
Azienda Ospedaliero-Universitaria Pisana
Professor
Department of Translational Research and New Technologies in Medicine and Surgery
University of Pisa
Pisa, Italy

Chiara Cremolini, MD, PhD, has disclosed that she has received funds for research support from Amgen, Bayer, and Merck and consulting fees from Bayer, Merck, MSD, Nordic Pharma, Pierre Fabre, and Roche.

Teresa Macarulla, MD

Medical Oncologist
Vall d Hebron Institute of Oncology
Barcelona, Spain

Teresa Macarulla, MD, has disclosed that she has received consulting fees from Ability, Advance Medical HCMS, AstraZeneca, Baxter, Celgene, Eisai, Genzyme, Incyte, Ispen, Lilly, Marketing Farmacéutico & Investigación Clínica SL, Merck Sharp and Dohme, QED, Roche, Sanofi, Servier, and Zymeworks.